News Commentary | April 14, 2021
Scientists at Singapore's Nanyang Technological University reported that recovering COVID‑19 patients with preexisting cardiovascular conditions may be at a higher risk of developing blood clots. The findings come at a time when vaccines from AstraZeneca and Johnson & Johnson have reported rare ... Not part of subscription
Analyst Insight | June 01, 2021
It's been a little over a year since the worst pandemic in a century closed businesses and homes to the outside world. Now, with the hope of multiple vaccines and both countries and companies beginning to advance through reopening processes, it's time to start laying the groundwork for future ... Not part of subscription
News Commentary | October 14, 2021
Nontraditional healthcare players are coming together to recognize some outstanding access and literacy challenges along the patient journey. Historically, underserved communities have not had positive experiences with healthcare systems, and there are significant challenges in reaching those ... Not part of subscription
by Nardev Ramanathan
Roche and Wellthy Therapeutics partnered last year to test self-management practices for Type 2 diabetes using Roche's Accu-Chek and Wellthy's digital therapeutic (DTx). The study found that those with the highest engagement with Wellthy's DTx saw the largest reduction in blood sugar levels. The results were especially encouraging because they were found in a real-world setting, as opposed to a clinical trial setting. Roche has moved quickly to build a digital diabetes management ecosystem in a resource-constrained and low-health-literacy market. This is a great example of a foreign multinational tailoring its approach to fit local market needs and partnering with a local startup that's well-placed to understand local consumer behavior.
For the original news article, click here .